Promoter methylation profiles between human lung adenocarcinoma multidrug resistant A549/cisplatin (A549/DDP) cells and its progenitor A549 cells

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 8, 2013, Pages 1310-1316

  Guo, Ruiling ^a   Wu, Guoming ^b   Li, Haidong ^a   Qian, Pin ^b   Han, Juan ^a   Pan, Feng ^a   Li, Wenbi ^a   Li, Jin ^b   Ji, Fuyun ^b  

^a The 324th Hospital of the Chinese People's Liberation Army   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

DNA methylation; Lung adenocarcinoma; Multidrug resistance; Promoter

Indexed keywords

CISPLATIN; MESSENGER RNA;

ARTICLE; BAD GENE; CANCER CELL; CCNL2 GENE; CELL DIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE SILENCING; GPR56 GENE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LUNG ADENOCARCINOMA; MT1G GENE; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; ONCOGENE; RASSF1 GENE;

EID: 84883166452     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00153     Document Type: Article

References (42)

1. Zhi XY. Advances in surgical treatment of non-small cell lung cancer. Oncology Progress, 7, 379-386 (2009a).
2. Zheng S, Qian P, Li F, Qian G, Wang C, Wu G, Li Q, Chen Y, Li J, Li H, He B, Ji F. Association of mitochondrial DNA variations with lung cancer risk in a Han Chinese population from southwestern China. PLoS ONE, 7, e31322 (2012).
3. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male : female differences diminishing and adenocarcinoma rates rising. Int. J. Cancer, 117, 294-299 (2005).
4. Solyanik GI. Multifactorial nature of tumor drug resistance. Exp. Oncol., 32, 181-185 (2010).
5. Zeng-Rong N, Paterson J, Alpert L, Tsao MS, Viallet J, Alaoui-Jamali MA. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res., 55, 4760-4764 (1995).
6. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene, 23, 2934-2949 (2004).
7. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene, 22, 7369-7375 (2003).
8. Mashima T, Tsuruo T. Defects of the apoptotic pathway as therapeutic target against cancer. Drug Resist. Updat., 8, 339-343 (2005).
9. Oza AM. Clinical development of P glycoprotein modulators in oncology. Novartis Found. Symp., 243, 103-115, discussion, 115-118, 180-185 (2002).
10. Choi CH. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int., 5, 30 (2005).
11. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - A mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer, 6, 107-116 (2006).
12. Nyce J. Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res., 49, 5829-5836 (1989).
13. Baker EK, El-Osta A. The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp. Cell Res., 290, 177-194 (2003).
14. Roberti A, La Sala D, Cinti C. Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drugresistant tumors: current views and new therapeutic prospective. J. Cell. Physiol., 207, 571-581 (2006).
15. Teodoridis JM, Strathdee G, Brown R. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist. Updat., 7, 267-278 (2004).
16. Brown R, Glasspool R. Epigenetic modulation of resistance to chemotherapy? Ann. Oncol., 18, 1429-1430 (2007).
17. Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP, Pogribny IP. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Mol. Cancer Ther., 6, 1089-1098 (2007).
18. Qiu YY, Mirkin BL, Dwivedi RS. Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells. Cancer Detect. Prev., 29, 456-463 (2005).
19. 1 gene promoter. Cancer Res., 60, 6039-6044 (2000).
20. Liu R, Hong Z. Relationship between methylation status of multidrug resistance protein (MRP) and multi-drug resistance in lung cancer cell lines. Chin. J. Cancer Res., 19, 277-282 (2007).
21. Guo R, Wu G, Ji F, Xu S. Methylation of DNA mismatch repair gene MLH1 and MSH2 in acquired multidrug-resistance of human small cell lung cancer cells H446. Acta Academiae Medicinae Militaris Tertiae, 29, 2247-2249 (2007).
22. Guo R, Wu G, Ji F, Huang G, Chen W. Preliminary study of mechanisms of docetacel on human lung adenocarcinoma multidrugresistant cells A549/CDDP and its parental cells. Acta Academiae Medicinae Militaris Tertiae, 27, 610-613 (2005).
23. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL, Schübeler D. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat. Genet., 37, 853-862 (2005).
24. Johnson DS, Li W, Gordon DB, Bhattacharjee A, Curry B, Ghosh J, Brizuela L, Carroll JS, Brown M, Flicek P, Koch CM, Dunham I, Bieda M, Xu X, Farnham PJ, Kapranov P, Nix DA, Gingeras TR, Zhang X, Holster H, Jiang N, Green RD, Song JS, McCuine SA, Anton E, Nguyen L, Trinklein ND, Ye Z, Ching K, Hawkins D, Ren B, Scacheri PC, Rozowsky J, Karpikov A, Euskirchen G, Weissman S, Gerstein M, Snyder M, Yang A, Moqtaderi Z, Hirsch H, Shulha HP, Fu Y, Weng Z, Struhl K, Myers RM, Lieb JD, Liu XS. Systematic evaluation of variability in ChIP-chip experiments using predefined DNA targets. Genome Res., 18, 393-403 (2008).
25. Scacheri PC, Crawford GE, Davis S. Statistics for ChIP-chip and DNase hypersensitivity experiments on NimbleGen arrays. Methods Enzymol., 411, 270-282 (2006).
26. O'Geen H, Nicolet CM, Blahnik K, Green R, Farnham PJ. Comparison of sample preparation methods for ChIP-chip assays. Biotechniques, 41, 577-580 (2006).
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-408 (2001).
28. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell, 128, 707-719 (2007).
29. Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br. J. Cancer, 94, 1087-1092 (2006).
30. Wang J, Wang B, Chen X, Bi J. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis. Carcinogenesis, 32, 411-416 (2011).
31. Chung JH, Lee HJ, Kim BH, Cho NY, Kang GH. DNA methylation profile during multistage progression of pulmonary adenocarcinomas. Virchows Arch., 459, 201-211 (2011).
32. Xu L, Begum S, Barry M, Crowley D, Yang L, Bronson RT, Hynes RO. GPR56 plays varying roles in endogenous cancer progression. Clin. Exp. Metastasis, 27, 241-249 (2010).
33. Ke N, Sundaram R, Liu G, Chionis J, Fan W, Rogers C, Awad T, Grifman M, Yu D, Wong-Staal F, Li QX. Orphan G protein-coupled receptor GPR56 plays a role in cell transformation and tumorigenesis involving the cell adhesion pathway. Mol. Cancer Ther., 6, 1840-1850 (2007).
34. Zhao QZ, Dou KF. Methylation of Ras association domain family protein 1, isoform A correlated with proliferation and drug resistance in hepatocellular carcinoma cell line SMMC-7721. J. Gastroenterol. Hepatol., 22, 683-689 (2007).
35. Huang Y, de la Chapelle A, Pellegata NS. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int. J. Cancer, 104, 735-744 (2003).
36. Koga Y, Pelizzola M, Cheng E, Krauthammer M, Sznol M, Ariyan S, Narayan D, Molinaro AM, Halaban R, Weissman SM. Genomewide screen of promoter methylation identifies novel markers in melanoma. Genome Res., 19, 1462-1470 (2009).
37. Boyes J, Bird A. Repression of genes by DNA methylation depends on CpG density and promoter strength: evidence for involvement of a methyl-CpG binding protein. EMBO J., 11, 327-333 (1992).
38. Tycko B. Epigenetic gene silencing in cancer. J. Clin. Invest., 105, 401-407 (2000).
39. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet., 9, 465-476 (2008).
40. Cheung HH, Lee TL, Davis AJ, Taft DH, Rennert OM, Chan WY. Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAs in human testicular cancer. Br. J. Cancer, 102, 419-427 (2010).
41. Eckhardt F, Lewin J, Cortese R, Rakyan VK, Attwood J, Burger M, Burton J, Cox TV, Davies R, Down TA, Haefliger C, Horton R, Howe K, Jackson DK, Kunde J, Koenig C, Liddle J, Niblett D, Otto T, Pettett R, Seemann S, Thompson C, West T, Rogers J, Olek A, Berlin K, Beck S. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat. Genet., 38, 1378-1385 (2006).
42. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet., 7, 21-33 (2006).